Optiscan has been featured in Stockhead’s quarterly healthcare wrap, highlighting the company’s significant regulatory, clinical and commercial progress during the September quarter as it advanced its human imaging platforms toward potential US market entry.

The article highlights Optiscan’s US FDA 510(k) submissions for its InForm digital pathology and InVue precision surgery platforms, alongside the expansion of its Mayo Clinic collaboration through breast and head and neck cancer studies evaluating both devices within integrated surgical-pathology workflows. It also notes continued progress across the company’s Australian clinical programs, including its breast cancer study at The Royal Melbourne Hospital, head and neck cancer study at St John of God Murdoch Hospital, and anatomical pathology study with Australian Clinical Labs, which had generated 84 datasets by 30 September.

On the commercial front, the article also highlights the US launch of InSpecta at the American Veterinary Medical Association Convention, along with investment in US business development and manufacturing capability.

CEO and Managing Director Dr. Camile Farah said: “These submissions are among the most significant milestones in Optiscan’s recent history...This has been a defining quarter for Optiscan, and I am incredibly proud of what our team has achieved.”

Read the full article here.